NCT06462014View on ClinicalTrials.gov

Description of Relugolix Use in Patients With Prostate Cancer Within the VHA

CompletedOBSERVATIONAL

Enrollment

500

Participants

Timeline

Start Date

June 19, 2024

Primary Completion Date

December 13, 2024

Study Completion Date

December 13, 2024

Conditions

Prostate Cancer

Interventions

DRUG

Relugolix

relugolix

Trial Locations (1)

10001

Pfizer, New York

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY